nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—AOX1—Methotrexate—muscle cancer	0.293	0.418	CbGbCtD
Zaleplon—CYP3A7—Vincristine—muscle cancer	0.0975	0.139	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0975	0.139	CbGbCtD
Zaleplon—CYP3A5—Vincristine—muscle cancer	0.0731	0.104	CbGbCtD
Zaleplon—CYP3A5—Etoposide—muscle cancer	0.067	0.0957	CbGbCtD
Zaleplon—CYP3A4—Vincristine—muscle cancer	0.0285	0.0407	CbGbCtD
Zaleplon—CYP3A4—Etoposide—muscle cancer	0.0261	0.0373	CbGbCtD
Zaleplon—CYP3A4—Doxorubicin—muscle cancer	0.0178	0.0254	CbGbCtD
Zaleplon—TSPO—hindlimb—muscle cancer	0.00431	0.163	CbGeAlD
Zaleplon—TSPO—appendage—muscle cancer	0.0037	0.14	CbGeAlD
Zaleplon—TSPO—embryo—muscle cancer	0.00123	0.0464	CbGeAlD
Zaleplon—AOX1—renal system—muscle cancer	0.00109	0.0411	CbGeAlD
Zaleplon—AOX1—cardiac atrium—muscle cancer	0.000974	0.0368	CbGeAlD
Zaleplon—TSPO—smooth muscle tissue—muscle cancer	0.000965	0.0365	CbGeAlD
Zaleplon—TSPO—renal system—muscle cancer	0.000929	0.0351	CbGeAlD
Zaleplon—AOX1—tendon—muscle cancer	0.000849	0.0321	CbGeAlD
Zaleplon—TSPO—cardiac atrium—muscle cancer	0.000832	0.0315	CbGeAlD
Zaleplon—AOX1—vagina—muscle cancer	0.000788	0.0298	CbGeAlD
Zaleplon—GABRB2—head—muscle cancer	0.000735	0.0278	CbGeAlD
Zaleplon—GABRG2—head—muscle cancer	0.000735	0.0278	CbGeAlD
Zaleplon—GABRA2—vagina—muscle cancer	0.000727	0.0275	CbGeAlD
Zaleplon—TSPO—tendon—muscle cancer	0.000725	0.0274	CbGeAlD
Zaleplon—GABRB2—testis—muscle cancer	0.00071	0.0268	CbGeAlD
Zaleplon—AOX1—testis—muscle cancer	0.000703	0.0266	CbGeAlD
Zaleplon—TSPO—bone marrow—muscle cancer	0.000702	0.0266	CbGeAlD
Zaleplon—TSPO—vagina—muscle cancer	0.000673	0.0254	CbGeAlD
Zaleplon—GABRA2—head—muscle cancer	0.000672	0.0254	CbGeAlD
Zaleplon—GABRA1—head—muscle cancer	0.000649	0.0245	CbGeAlD
Zaleplon—TSPO—head—muscle cancer	0.000622	0.0235	CbGeAlD
Zaleplon—TSPO—testis—muscle cancer	0.000601	0.0227	CbGeAlD
Zaleplon—CYP3A5—renal system—muscle cancer	0.000575	0.0218	CbGeAlD
Zaleplon—GABRB3—head—muscle cancer	0.000564	0.0213	CbGeAlD
Zaleplon—Immune system disorder—Etoposide—muscle cancer	0.000557	0.00204	CcSEcCtD
Zaleplon—Abnormal vision—Doxorubicin—muscle cancer	0.000555	0.00203	CcSEcCtD
Zaleplon—Chills—Etoposide—muscle cancer	0.000553	0.00203	CcSEcCtD
Zaleplon—Mental disability—Doxorubicin—muscle cancer	0.000553	0.00202	CcSEcCtD
Zaleplon—Anaphylactoid reaction—Methotrexate—muscle cancer	0.000552	0.00202	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000551	0.00202	CcSEcCtD
Zaleplon—GABRB3—testis—muscle cancer	0.000545	0.0206	CbGeAlD
Zaleplon—Alopecia—Etoposide—muscle cancer	0.000545	0.002	CcSEcCtD
Zaleplon—Lymphadenopathy—Doxorubicin—muscle cancer	0.000542	0.00198	CcSEcCtD
Zaleplon—Oedema—Vincristine—muscle cancer	0.000541	0.00198	CcSEcCtD
Zaleplon—Anaphylactic shock—Vincristine—muscle cancer	0.000541	0.00198	CcSEcCtD
Zaleplon—Thrombophlebitis—Doxorubicin—muscle cancer	0.000534	0.00196	CcSEcCtD
Zaleplon—Osteoarthritis—Methotrexate—muscle cancer	0.000534	0.00196	CcSEcCtD
Zaleplon—Diabetes mellitus—Doxorubicin—muscle cancer	0.000532	0.00195	CcSEcCtD
Zaleplon—Nervous system disorder—Vincristine—muscle cancer	0.00053	0.00194	CcSEcCtD
Zaleplon—Photosensitivity—Doxorubicin—muscle cancer	0.000526	0.00193	CcSEcCtD
Zaleplon—Decreased appetite—Dactinomycin—muscle cancer	0.000526	0.00193	CcSEcCtD
Zaleplon—Dysgeusia—Etoposide—muscle cancer	0.000526	0.00193	CcSEcCtD
Zaleplon—Hyperhidrosis—Vincristine—muscle cancer	0.000523	0.00191	CcSEcCtD
Zaleplon—Back pain—Etoposide—muscle cancer	0.000519	0.0019	CcSEcCtD
Zaleplon—Pain—Dactinomycin—muscle cancer	0.000518	0.0019	CcSEcCtD
Zaleplon—Vascular purpura—Doxorubicin—muscle cancer	0.000517	0.00189	CcSEcCtD
Zaleplon—Anorexia—Vincristine—muscle cancer	0.000515	0.00189	CcSEcCtD
Zaleplon—Eczema—Doxorubicin—muscle cancer	0.000514	0.00188	CcSEcCtD
Zaleplon—Eye pain—Doxorubicin—muscle cancer	0.000512	0.00188	CcSEcCtD
Zaleplon—Irritability—Methotrexate—muscle cancer	0.00051	0.00187	CcSEcCtD
Zaleplon—Mood swings—Methotrexate—muscle cancer	0.000506	0.00185	CcSEcCtD
Zaleplon—Hypotension—Vincristine—muscle cancer	0.000505	0.00185	CcSEcCtD
Zaleplon—Ataxia—Methotrexate—muscle cancer	0.000502	0.00184	CcSEcCtD
Zaleplon—Feeling abnormal—Dactinomycin—muscle cancer	0.000499	0.00183	CcSEcCtD
Zaleplon—Ill-defined disorder—Etoposide—muscle cancer	0.000498	0.00182	CcSEcCtD
Zaleplon—Anaemia—Etoposide—muscle cancer	0.000496	0.00182	CcSEcCtD
Zaleplon—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000495	0.00181	CcSEcCtD
Zaleplon—Liver function test abnormal—Methotrexate—muscle cancer	0.000493	0.00181	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000493	0.0018	CcSEcCtD
Zaleplon—Increased appetite—Doxorubicin—muscle cancer	0.000492	0.0018	CcSEcCtD
Zaleplon—Insomnia—Vincristine—muscle cancer	0.000489	0.00179	CcSEcCtD
Zaleplon—Paraesthesia—Vincristine—muscle cancer	0.000486	0.00178	CcSEcCtD
Zaleplon—Malaise—Etoposide—muscle cancer	0.000484	0.00177	CcSEcCtD
Zaleplon—Dermatitis bullous—Doxorubicin—muscle cancer	0.000484	0.00177	CcSEcCtD
Zaleplon—Breast disorder—Methotrexate—muscle cancer	0.000482	0.00177	CcSEcCtD
Zaleplon—Vertigo—Etoposide—muscle cancer	0.000482	0.00177	CcSEcCtD
Zaleplon—Purpura—Doxorubicin—muscle cancer	0.00048	0.00176	CcSEcCtD
Zaleplon—Abdominal pain—Dactinomycin—muscle cancer	0.000478	0.00175	CcSEcCtD
Zaleplon—Body temperature increased—Dactinomycin—muscle cancer	0.000478	0.00175	CcSEcCtD
Zaleplon—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000478	0.00175	CcSEcCtD
Zaleplon—Hypoglycaemia—Doxorubicin—muscle cancer	0.000474	0.00173	CcSEcCtD
Zaleplon—Loss of consciousness—Etoposide—muscle cancer	0.000472	0.00173	CcSEcCtD
Zaleplon—Decreased appetite—Vincristine—muscle cancer	0.00047	0.00172	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Vincristine—muscle cancer	0.000467	0.00171	CcSEcCtD
Zaleplon—Hypertension—Etoposide—muscle cancer	0.000463	0.0017	CcSEcCtD
Zaleplon—Pain—Vincristine—muscle cancer	0.000462	0.00169	CcSEcCtD
Zaleplon—Constipation—Vincristine—muscle cancer	0.000462	0.00169	CcSEcCtD
Zaleplon—Osteoarthritis—Doxorubicin—muscle cancer	0.000462	0.00169	CcSEcCtD
Zaleplon—Diplopia—Doxorubicin—muscle cancer	0.000462	0.00169	CcSEcCtD
Zaleplon—Asthma—Methotrexate—muscle cancer	0.000461	0.00169	CcSEcCtD
Zaleplon—Chest pain—Etoposide—muscle cancer	0.000457	0.00167	CcSEcCtD
Zaleplon—Eosinophilia—Methotrexate—muscle cancer	0.000457	0.00167	CcSEcCtD
Zaleplon—Migraine—Doxorubicin—muscle cancer	0.000455	0.00167	CcSEcCtD
Zaleplon—Affect lability—Doxorubicin—muscle cancer	0.000455	0.00167	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000454	0.00166	CcSEcCtD
Zaleplon—Discomfort—Etoposide—muscle cancer	0.000452	0.00165	CcSEcCtD
Zaleplon—Face oedema—Doxorubicin—muscle cancer	0.000446	0.00163	CcSEcCtD
Zaleplon—Gastrointestinal pain—Vincristine—muscle cancer	0.000442	0.00162	CcSEcCtD
Zaleplon—Confusional state—Etoposide—muscle cancer	0.000442	0.00162	CcSEcCtD
Zaleplon—Anaphylactic shock—Etoposide—muscle cancer	0.000438	0.0016	CcSEcCtD
Zaleplon—Mood swings—Doxorubicin—muscle cancer	0.000438	0.0016	CcSEcCtD
Zaleplon—Ataxia—Doxorubicin—muscle cancer	0.000435	0.00159	CcSEcCtD
Zaleplon—Asthenia—Dactinomycin—muscle cancer	0.000434	0.00159	CcSEcCtD
Zaleplon—CYP3A4—renal system—muscle cancer	0.000432	0.0163	CbGeAlD
Zaleplon—Dysuria—Methotrexate—muscle cancer	0.000431	0.00158	CcSEcCtD
Zaleplon—Tachycardia—Etoposide—muscle cancer	0.000428	0.00157	CcSEcCtD
Zaleplon—Abdominal pain—Vincristine—muscle cancer	0.000428	0.00157	CcSEcCtD
Zaleplon—Body temperature increased—Vincristine—muscle cancer	0.000428	0.00157	CcSEcCtD
Zaleplon—Liver function test abnormal—Doxorubicin—muscle cancer	0.000427	0.00156	CcSEcCtD
Zaleplon—Skin disorder—Etoposide—muscle cancer	0.000426	0.00156	CcSEcCtD
Zaleplon—Erectile dysfunction—Methotrexate—muscle cancer	0.000425	0.00156	CcSEcCtD
Zaleplon—Dry skin—Doxorubicin—muscle cancer	0.000424	0.00155	CcSEcCtD
Zaleplon—Hyperhidrosis—Etoposide—muscle cancer	0.000424	0.00155	CcSEcCtD
Zaleplon—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000422	0.00155	CcSEcCtD
Zaleplon—Photosensitivity reaction—Methotrexate—muscle cancer	0.000421	0.00154	CcSEcCtD
Zaleplon—Breast disorder—Doxorubicin—muscle cancer	0.000418	0.00153	CcSEcCtD
Zaleplon—Anorexia—Etoposide—muscle cancer	0.000418	0.00153	CcSEcCtD
Zaleplon—CYP3A5—vagina—muscle cancer	0.000417	0.0158	CbGeAlD
Zaleplon—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000416	0.00152	CcSEcCtD
Zaleplon—Pneumonia—Methotrexate—muscle cancer	0.000414	0.00152	CcSEcCtD
Zaleplon—Depression—Methotrexate—muscle cancer	0.00041	0.0015	CcSEcCtD
Zaleplon—Hypotension—Etoposide—muscle cancer	0.000409	0.0015	CcSEcCtD
Zaleplon—Gastritis—Doxorubicin—muscle cancer	0.000409	0.0015	CcSEcCtD
Zaleplon—Muscular weakness—Doxorubicin—muscle cancer	0.000408	0.00149	CcSEcCtD
Zaleplon—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000408	0.00149	CcSEcCtD
Zaleplon—Stomatitis—Methotrexate—muscle cancer	0.000401	0.00147	CcSEcCtD
Zaleplon—Conjunctivitis—Methotrexate—muscle cancer	0.0004	0.00146	CcSEcCtD
Zaleplon—Asthma—Doxorubicin—muscle cancer	0.0004	0.00146	CcSEcCtD
Zaleplon—Dysphagia—Doxorubicin—muscle cancer	0.0004	0.00146	CcSEcCtD
Zaleplon—Eosinophilia—Doxorubicin—muscle cancer	0.000396	0.00145	CcSEcCtD
Zaleplon—Sweating—Methotrexate—muscle cancer	0.000394	0.00144	CcSEcCtD
Zaleplon—Paraesthesia—Etoposide—muscle cancer	0.000393	0.00144	CcSEcCtD
Zaleplon—Haematuria—Methotrexate—muscle cancer	0.000392	0.00144	CcSEcCtD
Zaleplon—Dyspnoea—Etoposide—muscle cancer	0.000391	0.00143	CcSEcCtD
Zaleplon—Somnolence—Etoposide—muscle cancer	0.000389	0.00143	CcSEcCtD
Zaleplon—Angina pectoris—Doxorubicin—muscle cancer	0.000389	0.00143	CcSEcCtD
Zaleplon—Hepatobiliary disease—Methotrexate—muscle cancer	0.000389	0.00143	CcSEcCtD
Zaleplon—Epistaxis—Methotrexate—muscle cancer	0.000388	0.00142	CcSEcCtD
Zaleplon—Asthenia—Vincristine—muscle cancer	0.000388	0.00142	CcSEcCtD
Zaleplon—Bronchitis—Doxorubicin—muscle cancer	0.000384	0.00141	CcSEcCtD
Zaleplon—Rash—Dactinomycin—muscle cancer	0.000382	0.0014	CcSEcCtD
Zaleplon—Decreased appetite—Etoposide—muscle cancer	0.000381	0.00139	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Etoposide—muscle cancer	0.000378	0.00139	CcSEcCtD
Zaleplon—Constipation—Etoposide—muscle cancer	0.000375	0.00137	CcSEcCtD
Zaleplon—Pain—Etoposide—muscle cancer	0.000375	0.00137	CcSEcCtD
Zaleplon—Dysuria—Doxorubicin—muscle cancer	0.000374	0.00137	CcSEcCtD
Zaleplon—Pollakiuria—Doxorubicin—muscle cancer	0.000369	0.00135	CcSEcCtD
Zaleplon—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000365	0.00134	CcSEcCtD
Zaleplon—Weight increased—Doxorubicin—muscle cancer	0.000364	0.00133	CcSEcCtD
Zaleplon—Weight decreased—Doxorubicin—muscle cancer	0.000361	0.00132	CcSEcCtD
Zaleplon—Feeling abnormal—Etoposide—muscle cancer	0.000361	0.00132	CcSEcCtD
Zaleplon—Hyperglycaemia—Doxorubicin—muscle cancer	0.00036	0.00132	CcSEcCtD
Zaleplon—Nausea—Dactinomycin—muscle cancer	0.00036	0.00132	CcSEcCtD
Zaleplon—Pneumonia—Doxorubicin—muscle cancer	0.000358	0.00131	CcSEcCtD
Zaleplon—Gastrointestinal pain—Etoposide—muscle cancer	0.000358	0.00131	CcSEcCtD
Zaleplon—Dizziness—Vincristine—muscle cancer	0.000358	0.00131	CcSEcCtD
Zaleplon—Visual impairment—Methotrexate—muscle cancer	0.000356	0.0013	CcSEcCtD
Zaleplon—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000349	0.00128	CcSEcCtD
Zaleplon—Urticaria—Etoposide—muscle cancer	0.000348	0.00127	CcSEcCtD
Zaleplon—Stomatitis—Doxorubicin—muscle cancer	0.000347	0.00127	CcSEcCtD
Zaleplon—Abdominal pain—Etoposide—muscle cancer	0.000346	0.00127	CcSEcCtD
Zaleplon—Body temperature increased—Etoposide—muscle cancer	0.000346	0.00127	CcSEcCtD
Zaleplon—Conjunctivitis—Doxorubicin—muscle cancer	0.000346	0.00127	CcSEcCtD
Zaleplon—Eye disorder—Methotrexate—muscle cancer	0.000345	0.00126	CcSEcCtD
Zaleplon—Tinnitus—Methotrexate—muscle cancer	0.000344	0.00126	CcSEcCtD
Zaleplon—Sweating—Doxorubicin—muscle cancer	0.000342	0.00125	CcSEcCtD
Zaleplon—Rash—Vincristine—muscle cancer	0.000341	0.00125	CcSEcCtD
Zaleplon—Dermatitis—Vincristine—muscle cancer	0.000341	0.00125	CcSEcCtD
Zaleplon—Haematuria—Doxorubicin—muscle cancer	0.00034	0.00124	CcSEcCtD
Zaleplon—Headache—Vincristine—muscle cancer	0.000339	0.00124	CcSEcCtD
Zaleplon—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000337	0.00123	CcSEcCtD
Zaleplon—Epistaxis—Doxorubicin—muscle cancer	0.000336	0.00123	CcSEcCtD
Zaleplon—Immune system disorder—Methotrexate—muscle cancer	0.000334	0.00122	CcSEcCtD
Zaleplon—Chills—Methotrexate—muscle cancer	0.000331	0.00121	CcSEcCtD
Zaleplon—Alopecia—Methotrexate—muscle cancer	0.000326	0.0012	CcSEcCtD
Zaleplon—Mental disorder—Methotrexate—muscle cancer	0.000324	0.00119	CcSEcCtD
Zaleplon—Malnutrition—Methotrexate—muscle cancer	0.000322	0.00118	CcSEcCtD
Zaleplon—Nausea—Vincristine—muscle cancer	0.000321	0.00118	CcSEcCtD
Zaleplon—Hypoaesthesia—Doxorubicin—muscle cancer	0.000318	0.00117	CcSEcCtD
Zaleplon—Oedema peripheral—Doxorubicin—muscle cancer	0.000315	0.00115	CcSEcCtD
Zaleplon—Dysgeusia—Methotrexate—muscle cancer	0.000315	0.00115	CcSEcCtD
Zaleplon—Asthenia—Etoposide—muscle cancer	0.000314	0.00115	CcSEcCtD
Zaleplon—Back pain—Methotrexate—muscle cancer	0.000311	0.00114	CcSEcCtD
Zaleplon—Pruritus—Etoposide—muscle cancer	0.00031	0.00114	CcSEcCtD
Zaleplon—Visual impairment—Doxorubicin—muscle cancer	0.000308	0.00113	CcSEcCtD
Zaleplon—Eye disorder—Doxorubicin—muscle cancer	0.000299	0.00109	CcSEcCtD
Zaleplon—Ill-defined disorder—Methotrexate—muscle cancer	0.000298	0.00109	CcSEcCtD
Zaleplon—Tinnitus—Doxorubicin—muscle cancer	0.000298	0.00109	CcSEcCtD
Zaleplon—Anaemia—Methotrexate—muscle cancer	0.000297	0.00109	CcSEcCtD
Zaleplon—Malaise—Methotrexate—muscle cancer	0.00029	0.00106	CcSEcCtD
Zaleplon—Dizziness—Etoposide—muscle cancer	0.00029	0.00106	CcSEcCtD
Zaleplon—Immune system disorder—Doxorubicin—muscle cancer	0.000289	0.00106	CcSEcCtD
Zaleplon—Vertigo—Methotrexate—muscle cancer	0.000289	0.00106	CcSEcCtD
Zaleplon—Chills—Doxorubicin—muscle cancer	0.000287	0.00105	CcSEcCtD
Zaleplon—Alopecia—Doxorubicin—muscle cancer	0.000283	0.00103	CcSEcCtD
Zaleplon—Mental disorder—Doxorubicin—muscle cancer	0.00028	0.00103	CcSEcCtD
Zaleplon—Malnutrition—Doxorubicin—muscle cancer	0.000278	0.00102	CcSEcCtD
Zaleplon—Rash—Etoposide—muscle cancer	0.000276	0.00101	CcSEcCtD
Zaleplon—Dermatitis—Etoposide—muscle cancer	0.000276	0.00101	CcSEcCtD
Zaleplon—Headache—Etoposide—muscle cancer	0.000274	0.00101	CcSEcCtD
Zaleplon—Flatulence—Doxorubicin—muscle cancer	0.000274	0.001	CcSEcCtD
Zaleplon—Myalgia—Methotrexate—muscle cancer	0.000274	0.001	CcSEcCtD
Zaleplon—Arthralgia—Methotrexate—muscle cancer	0.000274	0.001	CcSEcCtD
Zaleplon—Chest pain—Methotrexate—muscle cancer	0.000274	0.001	CcSEcCtD
Zaleplon—Tension—Doxorubicin—muscle cancer	0.000273	0.001	CcSEcCtD
Zaleplon—Dysgeusia—Doxorubicin—muscle cancer	0.000273	0.000998	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000272	0.000996	CcSEcCtD
Zaleplon—Discomfort—Methotrexate—muscle cancer	0.00027	0.00099	CcSEcCtD
Zaleplon—Nervousness—Doxorubicin—muscle cancer	0.00027	0.00099	CcSEcCtD
Zaleplon—Back pain—Doxorubicin—muscle cancer	0.000269	0.000986	CcSEcCtD
Zaleplon—Confusional state—Methotrexate—muscle cancer	0.000265	0.000969	CcSEcCtD
Zaleplon—Anaphylactic shock—Methotrexate—muscle cancer	0.000262	0.000961	CcSEcCtD
Zaleplon—Nausea—Etoposide—muscle cancer	0.00026	0.000953	CcSEcCtD
Zaleplon—Ill-defined disorder—Doxorubicin—muscle cancer	0.000258	0.000946	CcSEcCtD
Zaleplon—Nervous system disorder—Methotrexate—muscle cancer	0.000257	0.000942	CcSEcCtD
Zaleplon—Anaemia—Doxorubicin—muscle cancer	0.000257	0.000942	CcSEcCtD
Zaleplon—Agitation—Doxorubicin—muscle cancer	0.000256	0.000937	CcSEcCtD
Zaleplon—Skin disorder—Methotrexate—muscle cancer	0.000255	0.000933	CcSEcCtD
Zaleplon—Hyperhidrosis—Methotrexate—muscle cancer	0.000254	0.000929	CcSEcCtD
Zaleplon—Malaise—Doxorubicin—muscle cancer	0.000251	0.000919	CcSEcCtD
Zaleplon—Vertigo—Doxorubicin—muscle cancer	0.00025	0.000916	CcSEcCtD
Zaleplon—Anorexia—Methotrexate—muscle cancer	0.00025	0.000916	CcSEcCtD
Zaleplon—Syncope—Doxorubicin—muscle cancer	0.00025	0.000914	CcSEcCtD
Zaleplon—Palpitations—Doxorubicin—muscle cancer	0.000246	0.000901	CcSEcCtD
Zaleplon—Hypotension—Methotrexate—muscle cancer	0.000245	0.000898	CcSEcCtD
Zaleplon—Loss of consciousness—Doxorubicin—muscle cancer	0.000245	0.000896	CcSEcCtD
Zaleplon—Hypertension—Doxorubicin—muscle cancer	0.00024	0.00088	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000239	0.000876	CcSEcCtD
Zaleplon—Insomnia—Methotrexate—muscle cancer	0.000237	0.000869	CcSEcCtD
Zaleplon—Arthralgia—Doxorubicin—muscle cancer	0.000237	0.000868	CcSEcCtD
Zaleplon—Chest pain—Doxorubicin—muscle cancer	0.000237	0.000868	CcSEcCtD
Zaleplon—Myalgia—Doxorubicin—muscle cancer	0.000237	0.000868	CcSEcCtD
Zaleplon—Anxiety—Doxorubicin—muscle cancer	0.000236	0.000865	CcSEcCtD
Zaleplon—Paraesthesia—Methotrexate—muscle cancer	0.000236	0.000863	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000235	0.000862	CcSEcCtD
Zaleplon—Discomfort—Doxorubicin—muscle cancer	0.000234	0.000858	CcSEcCtD
Zaleplon—Dyspnoea—Methotrexate—muscle cancer	0.000234	0.000857	CcSEcCtD
Zaleplon—Somnolence—Methotrexate—muscle cancer	0.000233	0.000854	CcSEcCtD
Zaleplon—Dry mouth—Doxorubicin—muscle cancer	0.000232	0.000849	CcSEcCtD
Zaleplon—Dyspepsia—Methotrexate—muscle cancer	0.000231	0.000846	CcSEcCtD
Zaleplon—Confusional state—Doxorubicin—muscle cancer	0.000229	0.000839	CcSEcCtD
Zaleplon—Decreased appetite—Methotrexate—muscle cancer	0.000228	0.000835	CcSEcCtD
Zaleplon—Oedema—Doxorubicin—muscle cancer	0.000227	0.000832	CcSEcCtD
Zaleplon—Anaphylactic shock—Doxorubicin—muscle cancer	0.000227	0.000832	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000227	0.00083	CcSEcCtD
Zaleplon—Pain—Methotrexate—muscle cancer	0.000224	0.000822	CcSEcCtD
Zaleplon—Shock—Doxorubicin—muscle cancer	0.000224	0.000819	CcSEcCtD
Zaleplon—Nervous system disorder—Doxorubicin—muscle cancer	0.000223	0.000816	CcSEcCtD
Zaleplon—Tachycardia—Doxorubicin—muscle cancer	0.000222	0.000812	CcSEcCtD
Zaleplon—Skin disorder—Doxorubicin—muscle cancer	0.000221	0.000808	CcSEcCtD
Zaleplon—Hyperhidrosis—Doxorubicin—muscle cancer	0.00022	0.000804	CcSEcCtD
Zaleplon—Anorexia—Doxorubicin—muscle cancer	0.000217	0.000793	CcSEcCtD
Zaleplon—Feeling abnormal—Methotrexate—muscle cancer	0.000216	0.000792	CcSEcCtD
Zaleplon—Gastrointestinal pain—Methotrexate—muscle cancer	0.000215	0.000786	CcSEcCtD
Zaleplon—Hypotension—Doxorubicin—muscle cancer	0.000212	0.000778	CcSEcCtD
Zaleplon—Urticaria—Methotrexate—muscle cancer	0.000208	0.000763	CcSEcCtD
Zaleplon—Body temperature increased—Methotrexate—muscle cancer	0.000207	0.00076	CcSEcCtD
Zaleplon—Abdominal pain—Methotrexate—muscle cancer	0.000207	0.00076	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000207	0.000758	CcSEcCtD
Zaleplon—Insomnia—Doxorubicin—muscle cancer	0.000206	0.000753	CcSEcCtD
Zaleplon—Paraesthesia—Doxorubicin—muscle cancer	0.000204	0.000747	CcSEcCtD
Zaleplon—Dyspnoea—Doxorubicin—muscle cancer	0.000203	0.000742	CcSEcCtD
Zaleplon—Somnolence—Doxorubicin—muscle cancer	0.000202	0.00074	CcSEcCtD
Zaleplon—Dyspepsia—Doxorubicin—muscle cancer	0.0002	0.000732	CcSEcCtD
Zaleplon—Decreased appetite—Doxorubicin—muscle cancer	0.000198	0.000723	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000196	0.000718	CcSEcCtD
Zaleplon—Constipation—Doxorubicin—muscle cancer	0.000194	0.000712	CcSEcCtD
Zaleplon—Pain—Doxorubicin—muscle cancer	0.000194	0.000712	CcSEcCtD
Zaleplon—Asthenia—Methotrexate—muscle cancer	0.000188	0.000689	CcSEcCtD
Zaleplon—Feeling abnormal—Doxorubicin—muscle cancer	0.000187	0.000686	CcSEcCtD
Zaleplon—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000186	0.00068	CcSEcCtD
Zaleplon—Pruritus—Methotrexate—muscle cancer	0.000186	0.00068	CcSEcCtD
Zaleplon—Urticaria—Doxorubicin—muscle cancer	0.000181	0.000661	CcSEcCtD
Zaleplon—Body temperature increased—Doxorubicin—muscle cancer	0.00018	0.000658	CcSEcCtD
Zaleplon—Abdominal pain—Doxorubicin—muscle cancer	0.00018	0.000658	CcSEcCtD
Zaleplon—Dizziness—Methotrexate—muscle cancer	0.000174	0.000635	CcSEcCtD
Zaleplon—Rash—Methotrexate—muscle cancer	0.000165	0.000606	CcSEcCtD
Zaleplon—Dermatitis—Methotrexate—muscle cancer	0.000165	0.000605	CcSEcCtD
Zaleplon—Headache—Methotrexate—muscle cancer	0.000164	0.000602	CcSEcCtD
Zaleplon—Asthenia—Doxorubicin—muscle cancer	0.000163	0.000597	CcSEcCtD
Zaleplon—Pruritus—Doxorubicin—muscle cancer	0.000161	0.000589	CcSEcCtD
Zaleplon—Nausea—Methotrexate—muscle cancer	0.000156	0.000571	CcSEcCtD
Zaleplon—Dizziness—Doxorubicin—muscle cancer	0.00015	0.00055	CcSEcCtD
Zaleplon—Rash—Doxorubicin—muscle cancer	0.000143	0.000525	CcSEcCtD
Zaleplon—Dermatitis—Doxorubicin—muscle cancer	0.000143	0.000524	CcSEcCtD
Zaleplon—Headache—Doxorubicin—muscle cancer	0.000142	0.000521	CcSEcCtD
Zaleplon—Nausea—Doxorubicin—muscle cancer	0.000135	0.000494	CcSEcCtD
